Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 36 results for bph

  1. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  2. Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG770)

    Evidence-based recommendations on transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves injecting a high-speed jet of water into the prostate to destroy some of the prostate tissue and widen the urethra.

    Interventional procedures guidance
    Published
    14 September 2023
    View recommendations

    Sections for IPG770

  3. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB315)

    NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .

    Medtech innovation briefing
    Published
    31 January 2023

  4. GreenLight XPS for treating benign prostatic hyperplasia (MTG74)

    Evidence-based recommendations on GreenLight XPS for benign prostatic hyperplasia.

    Medical technologies guidance
    Published
    29 November 2022
    View recommendations

    Sections for MTG74

  5. Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore,...

    Research recommendation
    Published
    30 September 2022

  6. iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)

    NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .

    Medtech innovation briefing
    Published
    21 September 2022

  7. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG737)

    Evidence-based recommendations on prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves positioning a temporary implant in the urethra to increase the flow of urine.

    Interventional procedures guidance
    Published
    21 September 2022
    View recommendations

    Sections for IPG737

  8. PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)

    NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .

    Medtech innovation briefing
    Published
    31 August 2021

  9. Further evidence to address uncertainties about the relative clinical and cost effectiveness of UroLift compared with Rezum, especially in the NHS, would be welcome. This should include: • exploring long-term clinical outcomes and reintervention rates after UroLift • assessing the suitability of UroLift for prostates larger than 80 ml and for those with an obstructive median lobe.

    guidance UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia Number MTG58 Date issued May 2021 Other

    Research recommendation
    Published
    10 August 2021

  10. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

    Medtech innovation briefing
    Published
    13 July 2021

  11. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)

    Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.

    Medical technologies guidance
    Published
    4 May 2021
    View recommendations

    Sections for MTG58

  12. The PLASMA system for transurethral resection and haemostasis of the prostate (MTG53)

    Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate.

    Medical technologies guidance
    Published
    6 January 2021
    View recommendations

    Sections for MTG53

  13. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

    Medical technologies guidance
    Published
    24 June 2020
    View recommendations

    Sections for MTG49

  14. Urolift – a community-based alternative treatment for Benign Prostatic Obstruction (BPO)

    lower urinary tract symptoms of benign prostatic hyperplasia. BPO describes the cause of lower urinary tract symptoms from...

    Shared learning
    Last updated
    10 March 2020

  15. Northampton General Day Case BPH service evaluation – adoption of Urolift

    patients as alternative to TURP for troublesome symptoms of Benign Prostate Hyperplasia (BPH) would result in cost and...

    Shared learning
    Published
    17 January 2020